Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 0.46 |
| ▸ | CA2 | P00918 | 13/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22897575 | 0.79 | SMN1; SMN2 (0.54) | — | |
| SCHEMBL29559776 | 0.79 | SMN1; SMN2 (0.54) | — | |
| Iprofenin SCHEMBL486656 | 0.79 | CA1 (0.58) | CA1CA2ALOX15TSHRCYP2C19 | |
| SCHEMBL11795645 | 0.75 | GAA (0.47) | CYP2C19 | |
| Disofenin SCHEMBL135703 | 0.74 | TDP1 (0.64) | CA1CA2ALOX15TSHRCYP2C19 | |
| Disofenin SCHEMBL29687882 | 0.73 | TDP1 (0.62) | CA1CA2ALOX15TSHRCYP2C19 | |
| SCHEMBL8461470 | 0.71 | NPC1 (0.52) | — | |
| SCHEMBL11216296 | 0.70 | PKM (0.39) | — | |
| SCHEMBL487084 | 0.69 | POLB (0.59) | ALOX15TSHRCYP2C19HIF1ATDP1 | |
| SCHEMBL487184 | 0.69 | MEN1 (0.66) | CA1CA2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8257735-B2 | Method of increasing the bioavailability of recombinant human insulin isophane in a patient | SDG, Inc (US) | 2012-09-04 | — | — | US | disclosed |
| US-20110135727-A1 | Hepatocyte Delivery Vehicle for Delivery of a Combination of Recombinant Human Regular Insulin and Recombinant Human Insulin Isophane to a Mammal | SDG, INC. | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135727-A1 | Hepatocyte Delivery Vehicle for Delivery of a Combination of Recombinant Human Regular Insulin and Recombinant Human Insulin Isophane to a Mammal | INSR, INSRR, IAPP | CA1 895/4885CA2 1276/4885ALOX15 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.